Citigroup maintains Buy on Telix, lowers target to $22
Citigroup analyst Laura Sutcliffe maintained a Buy rating on Telix Pharmaceuticals while lowering the price target to $22 from $22.5. This follows a separate Buy rating from HC Wainwright & Co. with a $20 target.
*this image is generated using AI for illustrative purposes only.
Citigroup analyst Laura Sutcliffe has maintained a Buy rating on Telix Pharmaceuticals (NASDAQ: TLX) while lowering the price target to $22. The revision adjusts the previous target of $22.5, reflecting updated valuation expectations.
Analyst Rating and Price Target
The research firm's continued endorsement supports the company's market position despite the reduced price objective.
| Metric | Value |
|---|---|
| Rating | Buy |
| Price Target | $22 |
The adjustment follows a previous endorsement by HC Wainwright & Co., where analyst Robert Burns reiterated a Buy rating with a price target of $20.
What factors contributed to the slight reduction in Citigroup's price target for Telix Pharmaceuticals?
How might the differing price targets from Citigroup and HC Wainwright influence investor sentiment?
What upcoming catalysts could drive Telix Pharmaceuticals' stock toward the new $22 price target?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
